Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remestemcel-L
- Development stage
- Unknown
- Lead developer
- Lonza
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraarticular, Intramuscular, Intrathecal, Intracoronary, Intramyocardial, Local Injection, Intrahepatic
01
Overview
Remestemcel-L (Prochymal) is an allogeneic, bone marrow-derived mesenchymal stem cell (MSC) therapy developed by Mesoblast (originally by Osiris Therapeutics). It consists of ex vivo cultured human mesenchymal stem cells (hMSCs) obtained from healthy adult volunteer donors. These cells possess potent immunomodulatory properties, including the ability to home to sites of tissue injury and inflammation, suppress T-lymphocyte proliferation, and reduce the production of pro-inflammatory cytokines. Remestemcel-L is primarily indicated for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD) and has been investigated for other inflammatory conditions such as Crohn's disease and acute respiratory distress syndrome (ARDS). It is administered via intravenous infusion.
- Brand names
- Prochymal
- Other names
- adult human mesenchymal stem cellsallogeneic human mesenchymal stem cellshMSCsremestemcel-L
Beyond the preview
Go deeper on remestemcel-L.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remestemcel-L.